S ince our last report on antithrornbotic therapy in 1995, 1 new information has been
published on the role of aspirin and other platelet-active drugs in the treatment and …

Coller24 to develop a monoclonal antibody. 25 The antibody was the first agent to enter
clinical trials, later followed by a peptide and several small-molecule competitive inhibitors of …

Leukocytes are recruited early and abundantly to experimentally injured vessels, in direct
proportion to cell proliferation and intimal growth. Activated circulating leukocytes and Mac-1 …

rich in PAI-1, the most potent naturally occurring inhibitor of fibrinolysis. Accordingly, more
platelets aggregate in response to fibrinolytic therapy, and these platelets secrete PAI-1 …

Background Antithrombotic therapy improves the prognosis of patients with acute coronary
syndromes, yet the syndromes remain a therapeutic challenge. We evaluated tirofiban, a …

Myocardial infarction occurring in young people with angiographically normal coronary
arteries is well described but the pathophysiology of this condition remains unknown …

A defining characteristic of vascular cells is their adhesive status. The predominant cells of
the blood vessel, endothelial cells (EC) and smooth muscle cells (SMC), are normally …

A number of polymorphisms of the platelet glycoprotein (GP) Ib-V-IX and IIb/IIIa complexes
have been described, and the PlA polymorphism of GP IIIa has been associated with …

depend on both metabolism and clearance. Most inhibitors are quite specific for the RGD
pocket in GP IIb/IIIa; abciximab also binds to the 3-subunit on vitronectin receptors (v 3). 1 …

Objectives. This study sought to determine the frequency of thrombocytopenia and its
relation with clinical outcomes in high risk patients undergoing percutaneous coronary …